Lawyers for Johnson & Johnson’s Ovarian Cancer Victims React to SCOTUS Decision in Purdue
Johnson & Johnson (JNJ)
Last johnson & johnson earnings: 4/14 06:31 am
Check Earnings Report
US:NYSE Investor Relations:
jnj.com
Company Research
Source: Business Wire
Beasley Allen: ‘We believe this decision should spell doom for J&J’s third bankruptcy plan’ WASHINGTON--(BUSINESS WIRE)--The U.S. Supreme Court has denied a $7 billion Purdue Pharmaceuticals bankruptcy plan which would have given the Sackler family, which founded the company, immunity from additional liability for their irresponsible actions in promoting the deadly use of opioids to the public and physicians.The Sackler family had agreed to provide up to $6 billion in funding in exchange for immunity from further legal action while protecting billions in other assets. But the court ruled 5-4 that bankruptcy law does not permit that kind of protection.The decision has significant implications for ongoing efforts by Johnson & Johnson (NYSE:JNJ) to seek bankruptcy protection in an effort to resolve tens of thousands of ovarian cancer claims tied to the use of the company’s talc-based products, including the Johnson’s Baby Powder and Shower to Shower brands.In response, the following i
Show less
Read more
Impact Snapshot
Event Time:
JNJ
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
JNJ alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
JNJ alerts
High impacting Johnson & Johnson news events
Weekly update
A roundup of the hottest topics
JNJ
News
- Nipocalimab pivotal Phase 3 trial demonstrates sustained disease control in FcRn class for a broad population of myasthenia gravis patients [Yahoo! Finance]Yahoo! Finance
- Nipocalimab pivotal Phase 3 trial demonstrates longest sustained disease control in FcRn class for broadest population of myasthenia gravis patients [Yahoo! Finance]Yahoo! Finance
- Nipocalimab pivotal Phase 3 trial demonstrates longest sustained disease control in FcRn class for broadest population of myasthenia gravis patientsPR Newswire
- Registrations Open for the 2024 Orphan Drugs and Rare Diseases Conference - Boston, MA, United States - October 17-18th, 2024 [Yahoo! Finance]Yahoo! Finance
- Johnson & Johnson's (NYSE:JNJ) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock? [Yahoo! Finance]Yahoo! Finance
JNJ
Earnings
- 4/16/24 - Beat
JNJ
Sec Filings
- 6/25/24 - Form 11-K/A
- 6/24/24 - Form 11-K
- 6/24/24 - Form 11-K
- JNJ's page on the SEC website